welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).
expertly curated content related to this topic
-
Carol Burke, MDPresident of the American College of Gas...
-
AEAPAF- Asociación Española de Afectados por la Poliposis Adenomatosa FamiliarAEAPAF is a non-profit Spanish organizat...
-
Hereditary Colorectal Cancerhttps://www.fapvoice.com/wp-content/uplo...
-
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive FibromatosisBackground: Desmoid tumors (also kn...
-
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polypos...This randomized phase II trial studies h...
-
Gideon Steinbach, MD, PhDDr. Steinbach's research is focused on g...
-
fap awareness...